BACKGROUND: Numerous patient- and disease-related factors increase the risk of rapid cognitive decline in patients with Alzheimer's disease (AD). The ability of pharmacological treatment to attenuate this risk remains undefined. METHODS: Pooled data from 14 randomized clinical studies of donepezil in the treatment of AD (N = 3748) were analyzed to identify predictors of fast decline and determine the effect of donepezil on the risk of fast decline. RESULTS: Young age and more severe baseline cognitive, global, or behavioral status were identified as independent predictors of faster decline in placebo-treated patients. Multivariate models indicated that donepezil treatment was associated with a 39% to 63% reduction in the risk of faster decline. CONCLUSIONS: These results correspond with previous findings, indicating relationships between age or baseline disease severity and rates of cognitive decline. Furthermore, they suggest that symptomatic therapy for AD could reduce the likelihood of faster decline in treated patients.
RCT Entities:
BACKGROUND: Numerous patient- and disease-related factors increase the risk of rapid cognitive decline in patients with Alzheimer's disease (AD). The ability of pharmacological treatment to attenuate this risk remains undefined. METHODS: Pooled data from 14 randomized clinical studies of donepezil in the treatment of AD (N = 3748) were analyzed to identify predictors of fast decline and determine the effect of donepezil on the risk of fast decline. RESULTS: Young age and more severe baseline cognitive, global, or behavioral status were identified as independent predictors of faster decline in placebo-treated patients. Multivariate models indicated that donepezil treatment was associated with a 39% to 63% reduction in the risk of faster decline. CONCLUSIONS: These results correspond with previous findings, indicating relationships between age or baseline disease severity and rates of cognitive decline. Furthermore, they suggest that symptomatic therapy for AD could reduce the likelihood of faster decline in treated patients.
Authors: P B Rosenberg; M M Mielke; D Han; J S Leoutsakos; C G Lyketsos; P V Rabins; P P Zandi; J C S Breitner; M C Norton; K A Welsh-Bohmer; I H Zuckerman; G B Rattinger; R C Green; C Corcoran; J T Tschanz Journal: Int J Geriatr Psychiatry Date: 2012-02-29 Impact factor: 3.485
Authors: Matthew E Peters; Sarah Schwartz; Dingfen Han; Peter V Rabins; Martin Steinberg; Joann T Tschanz; Constantine G Lyketsos Journal: Am J Psychiatry Date: 2015-01-13 Impact factor: 18.112
Authors: Peter J Snyder; Colleen E Jackson; Ronald C Petersen; Ara S Khachaturian; Jeffrey Kaye; Marilyn S Albert; Sandra Weintraub Journal: Alzheimers Dement Date: 2011-05 Impact factor: 21.566
Authors: Mili Parikh; Linda S Hynan; Myron F Weiner; Laura Lacritz; Wendy Ringe; C Munro Cullum Journal: Clin Neuropsychol Date: 2014-08-18 Impact factor: 3.535
Authors: Peter V Rabins; Sarah Schwartz; Betty S Black; Christopher Corcoran; Elizabeth Fauth; Michele Mielke; Jessica Christensen; Constantine Lyketsos; Joann Tschanz Journal: Alzheimers Dement Date: 2012-11-02 Impact factor: 21.566
Authors: Laura B Zahodne; Assawin Gongvatana; Ronald A Cohen; Brian R Ott; Geoffrey Tremont Journal: Am J Geriatr Psychiatry Date: 2013-04-28 Impact factor: 4.105
Authors: Roy Jones; David Wilkinson; Oscar L Lopez; Jeffrey Cummings; Gunhild Waldemar; Richard Zhang; Joan Mackell; Serge Gauthier Journal: Trials Date: 2011-10-26 Impact factor: 2.279
Authors: Richard Sherva; Alden Gross; Shubhabrata Mukherjee; Ryan Koesterer; Philippe Amouyel; Celine Bellenguez; Carole Dufouil; David A Bennett; Lori Chibnik; Carlos Cruchaga; Jorge Del-Aguila; Lindsay A Farrer; Richard Mayeux; Leanne Munsie; Ashley Winslow; Stephen Newhouse; Andrew J Saykin; John S K Kauwe; Paul K Crane; Robert C Green Journal: Alzheimers Dement Date: 2020-06-23 Impact factor: 16.655